(Q38174261)

30 August 2017

title

HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa? (English)

1 reference

30 August 2017

1 reference

1 reference

George Papatheodoridis

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373089%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Jiannis Vlachogiannakos

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373089%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

1 February 2014

1 reference

30 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373089%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

34 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373089%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

127-132

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24373089%20AND%20SRC:MED&resulttype=core&format=json

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.

12 June 2020

cites work

1 reference

Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment

21 January 2018

1 reference

Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review

21 January 2018

1 reference

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

Chronic hepatitis B: update 2009

21 January 2018

1 reference

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update

21 January 2018

1 reference

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

21 January 2018

1 reference

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

21 January 2018

1 reference

Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients

21 January 2018

1 reference

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B.

21 January 2018

1 reference

Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay

21 January 2018

1 reference

Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay.

21 January 2018

1 reference

A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B.

21 January 2018

1 reference

Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report

21 January 2018

1 reference

Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir

21 January 2018

1 reference

Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.

21 January 2018

1 reference

Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype

21 January 2018

1 reference

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

21 January 2018

1 reference

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis

21 January 2018

1 reference

A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum

21 January 2018

1 reference

A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

21 January 2018

1 reference

Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-α2a

21 January 2018

1 reference

Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patients

21 January 2018

1 reference

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

21 January 2018

1 reference

Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir

21 January 2018

1 reference